Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Comprehensive Look At Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease
The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps, according to new findings from St. Jude Children"s Research Hospital. The research appears in the July 27 online edition of the Proceedings of the National Academy of Sciences.
generic viagra online
Amendments To Encourage Innovation And Competitiveness In The Seed Sector
The Government of Canada announced changes to reduce regulatory burden and encourage innovation and competitiveness in the seed sector. Amendments to the Seeds Regulations will create a more flexible variety registration system with reduced regulation while continuing to maintain the integrity of seed certification and environmental, food, and feed safety. Purchase zoloft to treat depression.
News of the day
Maternal Immunity Not All Good For A Fetus
As a fetus does not mount an immune response to maternal proteins that cross the placenta, it has been assumed that a fetus would not reject non-genetically matched blood cells (specifically allogeneic blood cells) if they were transplanted while the fetus was in utero. The hope is that this procedure, which is known as IUHCT, could provide a viable approach for treating congenital blood disorders. However, studies using a mouse model of IUHCT indicate that most fetal recipients of allogeneic blood cells lose their transplanted cells 3-5 weeks after transplantation. Alan Flake and colleagues, at Children"s Hospital of Philadelphia, have now identified an immune mechanism responsible for graft failure in this model of IUHCT. Surprisingly, although fetal immune cells eliminated the transplanted allogeneic blood cells, they were triggered to do so by immune molecules known as alloantibodies that they obtained from their mother"s breast milk. The maternal alloantibodies were produced in response to IUHCT and so the authors conclude that in the absence of either a maternal immune response or transmission of the maternal alloantibodies to the fetus, transplanted blood cells should not be rejected, leaving open the door for IUHCT as a potential clinical strategy.
Mental Health

Blood Pressure Cuff Could Help Improve The Success Of Kidney Transplants

The first clinical trial funded by the new Efficacy and Mechanism Evaluation (EME) programme will investigate whether a simple procedure to activate one of the body"s natural defence mechanisms improves the function of kidneys after transplantation. This research is funded by the Medical Research Council and managed by the National Institute for Health Research. A team of investigators, from six kidney transplant centres in the UK and one in Holland, will be led by Raymond MacAllister, Professor of Clinical Pharmacology at UCL (University College London). The ÷£800,000 clinical trial will recruit 400 patients requiring kidney transplantation over a three year period. In transplantation, the blood supply to the kidney is interrupted during surgery and the damage that results can limit the life-span and functioning of the transplanted kidney. The trial will examine whether activating a natural protective reflex know as Remote Ischaemic Pre-Conditioning (RIPC), which makes organs resistant to injury that occurs when their blood supply is reduced, has an effect on the outcome of transplantation. RIPC is stimulated by reducing blood flow to the arm of both the kidney donor and recipient for short periods (using a blood pressure cuff). If RIPC protects the kidney, then the transplant should work more effectively and last longer. Professor MacAllister comments that "kidney transplantation transforms the lives of patients with kidney failure. However, there is a growing shortage of kidneys for transplantation and the number of patients on the transplant list is steadily increasing. The RIPC procedure is simple, safe, easily implemented and inexpensive; should this trial confirm that it improves kidney function, this innovation will be a major benefit to kidney transplant recipients. Maximising the functionality and life-span of the transplanted kidney will optimise the use of this scarce re, and therefore increase the number of patients who can receive a transplant." Professor Rajesh Thakker, Chairman of the EME Board said "this exciting project is the first to be funded by the newly established EME programme. This simple intervention could increase survival rates for patients needing kidneys and may impact across other types of transplantation as well". To view the full project details visit http://www.eme.ac.uk Efficacy and Mechanism Evaluation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009